Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scilex Holding Company (SCLX)
NASDAQ:SCLX
RESEARCH TOOLSreports
Scilex Holding Company (SCLX) Stock Price & Analysis
141 Followers
SCLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $6.55
Previous Close$1.94
Volume702.78K
Average Volume (3M)1.32M
Market Cap
$351.51M
Enterprise Value$461.75M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$112.05M
Price to Earnings (P/E)―
Beta1.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding181,189,935
10 Day Avg. Volume2,354,044
30 Day Avg. Volume1,317,389
Standard Deviation0.29
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-1.33
Price to Sales (P/S)23.55
Price to Cash Flow (P/CF)8.40
P/FCF Ratio8.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.82
Enterprise Value/Gross Profit14.87
Enterprise Value/Ebitda-5.60
Forecast
1Y Price Target
$8.00Price Target Upside323.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Scilex Holding Company News
PremiumCompany Announcements
Scilex Holding Settles Lawsuit, Continues Litigation Against Ex-President
PremiumCompany Announcements
Scilex Holding Explores Strategic Options for Semnur Pharmaceuticals
Bulls Say, Bears Say
Bulls Say
Commercial DevelopmentsScilex announced that it has received FDA approval of commercial manufacturing of Gloperba, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S.
Product EffectivenessElyxyb's efficacy for acute migraine treatment is supported by clinical data, showing significant pain relief.
Strategic FinancingStrategic financing transaction removes near-term overhang.
Bears Say
Financial PerformanceScilex reported a full-year net loss totaling $1.28 per share, which was substantively wider than the forecast for a net loss of only $0.87 per share.
Product Market TractionInability to achieve market traction with ZTlido, Elyxyb, or Gloperba due to greater-than-anticipated competitive pressures or setbacks in obtaining reimbursement and formulary access.
Stock ValuationLowering the 12-month price target to $8 from the previous $12 per share reflects the impact of dilution from the most recent equity financing and expectations for additional equity dilution going forward.
---
Ownership Overview
1.61% Insiders
3.43% Mutual Funds
7.67% Other Institutional Investors
87.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCLX FAQ
What was Scilex Holding Company’s price range in the past 12 months?
Scilex Holding Company lowest stock price was $0.73 and its highest was $6.55 in the past 12 months.
What is Scilex Holding Company’s market cap?
Currently, no data Available
When is Scilex Holding Company’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scilex Holding Company’s earnings last quarter?
Currently, no data Available
Is Scilex Holding Company overvalued?
According to Wall Street analysts Scilex Holding Company’s price is currently Undervalued.
Does Scilex Holding Company pay dividends?
Scilex Holding Company does not currently pay dividends.
What is Scilex Holding Company’s EPS estimate?
Scilex Holding Company’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scilex Holding Company have?
Scilex Holding Company has 181,189,940 shares outstanding.
What happened to Scilex Holding Company’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scilex Holding Company?
Among the largest hedge funds holding Scilex Holding Company’s share is GoalVest Advisory LLC. It holds Scilex Holding Company’s shares valued at 12K.
---
Scilex Holding Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (323.28% Upside)
$8.00 (323.28% Upside)
Insider Transactions
Bought Shares
Worth $228.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-63.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.03%
Trailing 12-Months
Company Description
Scilex Holding Company
Vickers Vantage Corp I is a blank check company.
---
SCLX Stock 12 Month Forecast
Average Price Target
$8.00
▲(323.28% Upside)
Technical Analysis
Best Analysts Covering SCLX
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+46.17%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +46.17% per trade.
---